BMY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Bristol-Myers Squibb Co.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
CEO
Giovanni Caforio
Employees
30250
Headquarters

430 E 29th St Fl 14
New York, New York 10016-8367
Phone: 12125464000
www.bms.com

News

Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb
Feb 26, 2024 16:59pm

No summary available.


Source:Seeking Alpha
Bristol Myers Squibb launches Rs 828-cr innovation hub in Hyderabad
Feb 26, 2024 11:50am

Hyderabad: Biopharmaceutical giant Bristol Myers Squibb inaugurated its latest facility in Hyderabad on Monday, February 26, expanding its global presence. The new facility, which can house over 1,500 employees, has been built with an investment of more than $100 million (nearly Rs 828 crore). Bristol Myers Squibb hopes to further its goal of creating innovative … Get the latest updates in Hyderabad City News , Technology , Entertainment , Sports , Politics and Top Stories on WhatsApp & Telegram by subscribing to our channels. You can also download our app for Android and iOS .


Source:The Siasat Daily
Bristol Myers Squibb opens innovation hub in Hyderabad
Feb 26, 2024 10:15am

Bristol Myers Squibb (BMS) has opened an innovation hub in Hyderabad, India, to expand its global drug development, information technology, and digital capabilities. The facility, expected to house over 1,500 employees, represents an investment of over $100 million. BMS aims to accelerate drug development, enhance digital capabilities, and diversify its global workforce by tapping into local talent in Hyderabad.


Source:Economic Times India
5 Best Stocks to Buy Before US Election Season 2024
Feb 24, 2024 19:31pm

This article presents an overview of the 5 Best Stocks to Buy Before US Election Season 2024. For a detailed overview of such stocks, read our article 10 Best Stocks to Buy Before US Election Season 2024. 5. Bristol-Myers Squibb Co (NYSE:BMY) Number of Hedge Fund Investors: 60 Bristol-Myers Squibb Co (NYSE:BMY) is one of the best stocks […]


Source:Insider Monkey
Bristol Myers Squibb: Approx. 86% Of RayzeBio Common Stock Validly Tendered As Of Expiration Time
Feb 23, 2024 12:36pm

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said its tender offer to acquire all of the outstanding shares of RayzeBio, Inc. (RYZB) common stock for a purchase price of $62.50 per share i…


Source:Finanz Nachrichten
Bristol Myers blood disorder therapy endorsed in EU for label expansion
Feb 23, 2024 12:30pm

No summary available.


Source:Seeking Alpha
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Feb 23, 2024 11:59am

Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
Feb 23, 2024 11:59am

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Reblozyl for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk…


Source:Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
Feb 23, 2024 11:59am

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl (luspatercept) as a treatment for adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The recommendation will now be reviewed by the European Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Bristol-Myers Squibb’s $11 Billion Notes Issuance for Acquisitions
Feb 22, 2024 21:40pm

Bristol-Myers Squibb (BMY) has released an update. Bristol-Myers Squibb Company successfully completed a public offering on February 22, 2024, issu…


Source:TipRanks